Article Text

other Versions

PDF
The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders
  1. Malin Hultqvist (malin.hultqvist{at}med.lu.se)
  1. Experimental Medical Science, Sweden
    1. Kutty Selva Nandakumar (nan{at}med.lu.se)
    1. Medical Inflammation Research, Sweden
      1. Ulf Björklund (ulf.bjorklund{at}oxypharma.com)
      1. Oxypharma AB, Sweden
        1. Rikard Holmdahl (rikard.holmdahl{at}ki.se)
        1. Lund University, Sweden

          Abstract

          Objectives: Autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) affect a relatively large portion of the population, leading to severe disability if left untreated. Even though pharmaceutics targeting the immune system have revolutionized the therapy of these diseases, there is still a need for novel, more effective therapeutic substances. One such substance is the new chemical entity 9-chloro-2,3 dimethyl-6-(N,N-dimthylamino-2-oxoethyl)-6H-indolo [2,3-b] quionoxaline, Rabeximod, that is currently being investigated for efficiency in treatment of human RA. In this study we aimed to evaluate Rabeximod as a treatment for autoimmune diseases, using animal models.

          Methods: In the present investigation we have evaluated Rabeximod as a treatment for autoimmune diseases using mouse models of RA and MS, i.e. collagen-induced arthritis, collagen antibody induced arthritis and experimental autoimmune encephalomyelitis.

          Results: Rabeximod efficiently prevented both arthritis and encephalomyelitis in mice. In addition, this effect correlated to the time-point when cells migrate into the joints.

          Conclusions: We conclude that Rabeximod reduces disease severity in animal models of autoimmunity and should be considered as a new therapeutic substance for MS and RA.

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.